- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04473937
Radiation Post-CAR T in Refractory Lymphoma
Radiation Therapy To Enhance CAR T Efficacy Early in Post-CAR T Cell Therapy Refractory Lymphoma: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Pilot Study, which is the first time investigators are examining this intervention after administration of CAR T cell therapy. This research study looks to systematically investigate the safety and efficacy of radiotherapy following CAR T cell therapy (axicel or tisacel) in refractory lymphoma. CAR T cell therapy involves genetically modifying T cells to target tumor cells for death. Radiotherapy is a standard treatment offered with refractory lymphoma and uses high-energy x rays, or particles, to destroy or damage cancer cells. Few have received CAR T cell therapy prior to radiation therapy and this study aims to gather more information on radiotherapy following CAR T cell therapy as a treatment option and its potential to improve participants immune system's response to cancer cells as well as its interaction with CAR T cell therapy to better treat refractory lymphoma.
The research study procedures include screening for eligibility, enrollment, biopsy following radiation, post-treatment period, and long-term follow-up.
- Participants will receive radiotherapy at a dose and schedule determined by the study doctor.
- Participants will be followed for up to 24 months after completion of study treatment.
It is expected that about 20 people will take part in this research study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chirayu G Patel, MD, MPH
- Phone Number: 617-724-2340
- Email: cpatel@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
Principal Investigator:
- Matthew J Frigault, MD
-
Contact:
- Chirayu G Patel, MD, MPH
- Phone Number: 617-724-2340
- Email: cpatel@mgh.harvard.edu
-
Principal Investigator:
- Chirayu G Patel, MD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be able to undergo biopsy. Biopsy will be obtained for patients to exclude possibility of false negative residual FDG avidity on PET/CT that is not substantially increased relative to pre-CAR-T PET/CT. Exceptions are allowed for patients who have clearly progressive disease for whom delaying radiation therapy to obtain a biopsy may worsen outcome (such as cases of cord compression), and for patients for whom the risks of biopsy are high (such as patients with evidence for CNS involvement).
- Biopsy-confirmed refractory disease within 30-90 days following commercial axicabtagene ciloleucel or tisagenlecleucel therapy for a hematologic malignancy (these include relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma). Of note, 'refractory' refers to patients who had early refractory disease after CAR-T cell therapy and not to patients who have received CAR-T for refractory disease, but had complete response to CAR-T cell therapy.
- At least 1 measurable lesion according to the Lugano criteria1. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
The following criteria pertain to pattern of progression:
- Patients may have one refractory lesion without other residual or progressive disease as per PET/CT
- Patients may have more than one refractory lesion, but with evidence for at least partial response of at least one other lesion as per PET/CT
Patients with more than one site of refractory disease without evidence for at least partial response of at least one other lesion are eligible if they are:
- A. Symptomatic from a refractory lesion (such as cord compression or focal pain) or
- B. Have disease that can locally affect the spinal canal or brain if left untreated.
- Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia and prolonged cytopenias that are not expected to worsen during RT) if there is concern for overlap of anticipated radiation-related toxicity and toxicity from prior therapy due to where the RT field is located.
- Age 18 or older
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Any medical condition likely to interfere with assessment of safety or efficacy of RT
- Patients with more than one site of disease without any evidence for response to CAR T cell therapy who are not focally symptomatic due to progressive disease or do not have disease that can locally affect the spinal canal or brain if left untreated
- Women of child-bearing potential who are pregnant because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.
- In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiotherapy
Participants must have received CAR-T infusion within the last 90 days prior to completing a study screening and enrollment process.
|
Radiotherapy at pre-determined dose and schedule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Time Frame: 30 days
|
Rate and severity of radiotherapy-related toxicity as per CTCAE v5.0 criteria during radiotherapy (RT) or within the first 30 days of completing RT.
The number of participants who experienced radiotherapy-related toxicity are listed below.
Only one radiotherapy-related toxicity was observed - Grade 2 Dermatitis.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: Up to 2 years
|
DOR is defined as the length of time between a subject's first objective response per Lugano criteria (complete response or partial response) and local disease progression per Lugano criteria, or death regardless of cause.
|
Up to 2 years
|
Objective Response Rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the incidence of either a complete response or a partial response by Lugano criteria.
All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders.
|
Up to 2 years
|
Progression-free Survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from radiotherapy completion date to the date of disease progression per Lugano criteria or death from any cause.
Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.
|
Up to 2 years
|
Overall Survival
Time Frame: Up to 2 years
|
Overall survival is defined as the time from radiotherapy completion to the date of death.
Subjects who have not died by the analysis cutoff date will be censored at their last contact date.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chirayu G Patel, MD, MPH, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-861
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Lymphoma
-
Yazeed SawalhaWithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
The Lymphoma Academic Research OrganisationActive, not recruitingRefractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell LymphomaFrance
-
Narendranath EpperlaWithdrawnRecurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditionsUnited States
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterMustang BioRecruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
The Lymphoma Academic Research OrganisationLymphoma Study AssociationNot yet recruitingRefractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell LymphomaFrance
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditionsUnited States
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
Mediterranean Institute of OncologyUniversity of Palermo; University of MessinaRecruitingQuality of Life | Neurocognitive Deficit | Activities of Daily LivingItaly
-
Changhai HospitalRecruiting